Back to Search Start Over

Peripheral T-cell lymphomas as fingolimod-associated lymphoproliferative disorder for patients with multiple sclerosis - case report with literature review.

Authors :
Kawai, Hidetsugu
Matsushita, Hiromichi
Akashi, Hibiki
Furuya, Daisuke
Kawakami, Shohei
Suzuki, Rikio
Moriuchi, Makiko
Ogawa, Yoshiaki
Kawada, Hiroshi
Nakamura, Naoya
Ando, Kiyoshi
Source :
Leukemia & Lymphoma; Apr2020, Vol. 61 Issue 4, p959-962, 4p
Publication Year :
2020

Abstract

Over the past 25 years, the application of immunomodulating and immunosuppressive agents in the treatment of multiple sclerosis (MS), an autoimmune demyelinating and neurodegenerative disease, has led to improvements in clinical outcomes [[1]]. The induction of diffuse large B cell lymphoma (DLBCL) by methotrexate in arthritis patients and the induction of hepatosplenic T-cell lymphoma by infliximab (anti-human tumor necrosis factor-alfa antibody) in patients with inflammatory bowel diseases are typical examples [[14]]. Patients with primary cutaneous CD30-positive ALCL generally have a good prognosis, and three patients with cutaneous CD30-positive ALCL (no. 2-4) remained alive for 2-18 months (Table 1). Spontaneous regression of tumor-stage cutaneous T-cell lymphoma in a multiple sclerosis patient after discontinuing fingolimod. [Extracted from the article]

Details

Language :
English
ISSN :
10428194
Volume :
61
Issue :
4
Database :
Complementary Index
Journal :
Leukemia & Lymphoma
Publication Type :
Academic Journal
Accession number :
142373013
Full Text :
https://doi.org/10.1080/10428194.2019.1691197